Martin Fan

Stock Analyst at Wedbush

(4.96)
# 166
Out of 5,182 analysts
28
Total ratings
70.83%
Success rate
90.93%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Martin Fan

Nektar Therapeutics
Apr 21, 2026
Maintains: Neutral
Price Target: $70$95
Current: $86.74
Upside: +9.53%
Oruka Therapeutics
Apr 15, 2026
Maintains: Outperform
Price Target: $45$85
Current: $76.39
Upside: +11.27%
Sana Biotechnology
Apr 14, 2026
Maintains: Outperform
Price Target: $6$7
Current: $3.26
Upside: +114.72%
Vor Biopharma
Mar 31, 2026
Maintains: Neutral
Price Target: $9$15
Current: $14.12
Upside: +6.23%
Aclaris Therapeutics
Mar 31, 2026
Reiterates: Outperform
Price Target: $8
Current: $4.41
Upside: +81.41%
AnaptysBio
Mar 12, 2026
Maintains: Outperform
Price Target: $60$75
Current: $66.59
Upside: +12.63%
Cartesian Therapeutics
Mar 10, 2026
Reiterates: Outperform
Price Target: $38
Current: $7.07
Upside: +437.48%
Zura Bio
Feb 9, 2026
Initiates: Outperform
Price Target: $15
Current: $5.41
Upside: +177.26%
Zenas BioPharma
Dec 22, 2025
Reiterates: Outperform
Price Target: $45
Current: $18.59
Upside: +142.07%
ImageneBio
Nov 25, 2025
Assumes: Underperform
Price Target: $2
Current: $5.83
Upside: -65.69%
Maintains: Outperform
Price Target: $18$23
Current: $10.75
Upside: +113.95%